Auleon Biologicals
News
14
2026
-
07
Building Momentum to Break the Impasse and Forge Ahead Against the Trend—AOLONG Bio’s First-Half 2026 Marketing Summary Meeting Concludes Successfully!
Author:
As the first half of the year draws to a close, we set out once again on a new journey—building momentum to break through and surmount challenges, forging ahead against the odds!
From July 9 to July 10, 2026, Chongqing Aolong Biological Products Co., Ltd. (hereinafter referred to as Aolong Bio) held its “Building Momentum to Break the Impasse and Rise Against the Trend” first-half 2026 marketing summary conference in the Grand Conference Room on the third floor of the Administrative Center. The meeting comprehensively reviewed the performance of the company’s marketing efforts in the first half of the year, conducted an in-depth analysis of operational challenges, pain points, and bottlenecks, and thoroughly assessed the current industry market landscape. It also formulated precise plans for the second-half priorities and target objectives, aligned all employees around a shared vision of progress, and rallied the team to pool resources and tackle key issues, striving with full commitment to achieve the year’s goals and further enhance the company’s product market share and competitive edge.
Li Haijiang, President of Zhejiang Hengtong Holding Co., Ltd. and Chairman of Aolong Bio, along with Wang Bo, Director of the President’s Office at Zhejiang Hengtong Holding Co., Ltd., attended the conference to offer guidance and support, jointly charting a course for future development. Fu Gang, General Manager of Aolong Bio, led the company’s senior executives, all members of the Marketing Center, and heads of the Production, R&D, and Quality Management departments in attending the meeting.
Turning the blade inward to break the deadlock, we are building momentum and uniting our forces to usher in a new chapter. At the outset of the meeting, Fu Gang, General Manager of Aolong Bio, delivered an opening address, emphasizing that this summary conference is a pivotal occasion for reflection, identifying gaps, addressing shortcomings, and rallying collective strength to break through challenges. He underscored that post‑mortem analysis must go beyond mere summaries and vague statements; each business segment and regional market must ground their assessments in data, systematically review performance metrics, conduct a detailed diagnosis of issues, objectively evaluate successes and failures, and squarely confront existing weaknesses. Leaders responsible for each business unit are expected to provide targeted feedback and implement precise, actionable measures, ensuring that the review is thorough, the strategic planning ambitious, and execution resolute—thus guaranteeing the steady implementation and successful completion of the company’s annual strategic objectives.
Subsequently, the business managers of the five major divisions—cattle and sheep seedlings, government procurement, piglets, and foreign trade—each presented a mid-year performance review, drawing on their respective roles and benchmarking against actual results. They provided a detailed analysis of each division’s progress in achieving targets, market‑development achievements, customer‑relationship management, as well as the challenges and issues they face. In turn, Deputy General Managers Sun Shaoxun (in charge of the cattle‑seedling segment), Peng Zhi (responsible for the sheep‑seedling segment), and Wang Chengzhuo (overseeing the government‑procurement segment) offered targeted, in‑depth comments and analyses based on the presentations from their respective business units.
▲ Sun Shaoxun, Deputy General Manager of Aolong Bio, provided targeted and in-depth commentary and analysis on the cattle‑seedling segment.
▲ Deputy General Manager Peng Zhi provided targeted and in-depth commentary and analysis on the lamb‑raising segment.
▲ Deputy General Manager Wang Chengzhuo provided targeted and in-depth commentary and analysis on the government procurement sector.
Recognizing our shortcomings, we press forward; gazing at the distant mountains, we forge ahead. Following a comprehensive review and evaluation across all business segments, Fu Gang, General Manager of Aolong Bio, conducted a thorough retrospective of the marketing team’s performance and operational status for the first half of 2026, and laid out detailed plans for the strategic objectives, key tasks, and requirements for the second half of the year.
▲ Fu Gang, General Manager of Aolong Bio, conducted a comprehensive review of the marketing team’s performance and operational status for the first half of 2026, and laid out detailed plans for the strategic objectives, key tasks, and requirements for the second half of the year.
Fu Gang stated that in the first half of the year, the company set a baseline target of RMB 235 million for the full year and aimed to push toward RMB 250 million. Cumulative sales revenue reached RMB 136.2189 million, up RMB 8.9255 million year over year, while net profit stood at RMB 40 million. Overall, the business maintained steady progress, demonstrating strong, well-rounded competitiveness. Looking ahead to the second half, he laid out clear expectations and emphasized that, for the currently challenging cattle‑related business segment, all employees must prioritize it, take proactive measures, deepen expert collaboration and technical support, focus on key corporate clients, and make every effort to break into new market segments. Meanwhile, the sheep‑related business should zero in on core products, penetrate lower‑tier markets to expand growth opportunities, strengthen brand marketing, and accelerate the development and deployment of new offerings—building momentum for the company’s sustainable, high‑quality growth. As for the government procurement segment, greater investment in staff training is needed to identify and address gaps through real‑world application, continuously enhancing service efficiency and professional capabilities. Finally, the foreign trade segment, as a long‑term and demanding undertaking, must maintain strategic resolve, proceed steadily and methodically, and advance in an orderly manner.
General Manager Fu stated that, despite the current modest growth rate, he remains confident that, with the support and empowerment of Hengtong Shares, Aolong Bio’s future holds great promise. All members of the Aolong team should devote themselves wholeheartedly and press ahead with unwavering dedication, ensuring that every task is implemented effectively through a down-to-earth, results-oriented approach, and striving to write a new chapter in the company’s high-quality development.
▲ Wang Bo, Director of the President’s Office at Zhejiang Hengtong Holding Co., Ltd., delivered an important address after hearing the marketing team’s work report.
After listening to the marketing team’s work report, Wang Bo, Director of the President’s Office at Zhejiang Hengtong Holding Co., Ltd., conducted an in-depth analysis of the current industry cycle and market dynamics, and set forth specific requirements for Aolong Bio’s future strategic execution, marketing efforts, and internal capability‑building. He noted that, amid intensifying competition in the veterinary vaccine sector and a new phase of profound structural adjustment and comprehensive reshuffling, Aolong Bio’s various business units have advanced in concert, demonstrating robust resilience and vitality—instilling in Hengtong Shares strong confidence in Aolong Bio’s ability to navigate the current industry cycle and achieve sustained long-term growth.
Wang Bo stated that industry cycles may ebb and flow, but the underlying principle of survival of the fittest—where only the strongest endure—remains unchanged. Aolong Bio is a young, dynamic team with tremendous growth potential, backed by the robust financial strength of Hengtong Shares and the Hengtong Group, giving it ample confidence and no need to shy away from challenges. Looking ahead, Hengtong Shares will precisely align with customer needs and pain points, advancing its “extreme cost reduction and lean operations” philosophy through technological empowerment, intelligent upgrades, enhanced R&D innovation, and the development of differentiated business strategies, thereby strengthening Aolong Bio’s core competitiveness across multiple dimensions. At the same time, we hope that all employees of Aolong Bio will continue to uphold and carry forward Hengtong Shares’ spirit of “daring to lead, striving for excellence, scaling new heights, and pioneering great achievements,” using strategic resolve to navigate market volatility, building solid internal capabilities to seize opportunities, and positioning themselves at the forefront of the industry during this major reshuffle.
▲ Li Haijiang, President of Zhejiang Hengtong Holding Co., Ltd. and Chairman of Aolong Bio, delivered an important address after hearing the marketing team’s work report.
After listening to the marketing team’s work report, Li Haijiang, President of Zhejiang Hengtong Holding Co., Ltd. and Chairman of Aolong Bio, expressed his high appreciation for the company’s achievement of RMB 136 million in sales and RMB 40 million in profit during the first half of the year—despite challenging market conditions. He also outlined a clear roadmap for Aolong Bio’s leap‑forward, high‑quality development, bolstering confidence and energizing the team.
Li Haijiang stated that, amid mounting market challenges and the dual pressures of industry-wide “involution,” it has been no easy feat for Aolong Bio to achieve such results. These accomplishments are the fruit of the relentless efforts and hard work of Aolong’s management team—led by General Manager Fu Gang—and all frontline employees. Coupled with the company’s existing market positioning and its team’s strengths, he expressed full confidence that Aolong Bio will double both its revenue and profits in the years ahead. He emphasized that Hengtong Shares’ acquisition of Aolong Bio is far from a mere change in equity or a simple consolidation of entities; rather, it represents a major strategic move rooted in long-term vision, deep industry engagement, and proactive adaptation to change. The goal is to provide comprehensive support for Aolong Bio’s high‑quality development, working together to make the company stronger, better, and larger.
In the face of an ever‑changing market landscape, going forward, all members of the Aolong team must maintain a strong sense of urgency, vigilance, responsibility, and mission, driving transformation and breaking new ground with unwavering goals and convictions. At the same time, we must zero in on our customers’ most pressing pain points and challenges, leveraging multidimensional efforts across core technologies and product offerings to forge new growth trajectories. We will also refine our strategic positioning to capitalize on our unique strengths, accelerate our international expansion, and build differentiated competitive advantages—paving the way for Aolong to lead the charge and usher in a new era of high‑quality development.
With hearts united and resolve to break the deadlock, we are poised to ride the tide of opportunity. The first half of 2026 has now come to a close, and the clarion call for the second half has officially sounded. Looking ahead, all members of the Aolong family will take this mid-year conference as a fresh starting point—aligning our thinking, forging consensus, working with unwavering dedication, and boldly tackling challenges. With a renewed spirit, a fresh posture, and enhanced effectiveness, we will implement every strategic initiative, rally our efforts to sprint toward our annual goals, and join hands to chart a new course for the company’s high‑quality development.
Latest Blog
Thank you for visiting the official website of Chongqing Auleon Biologicals. If you have cooperation intentions or suggestions, please contact us through the following methods, and we will give you feedback in time, thank you!
Marketing Center: +86-023-46761801
Technical Services: +86-023-46763511
HR: +86-023-46763267
International Trade: +86-023-46763211
Address: (No.5, 4th Branch Road) National High-tech Industrial Park, Rongchang District, Chongqing, China
© 2024 Chongqing Auleon Biologicals Co., Ltd. 
渝公网安备50022602000038号